My career is focused on phase 1 and proof-of-mechanism clinical trials that are testing new targeted therapies and novel therapeutic strategies. While I conduct trials appropriate for a broad range of solid tumors, I am particularly interested in new drug development for gastrointestinal malignancies. Currently, I am developing several protocols appropriate for specific molecularly defined patient cohorts, including those whose tumors are dependent on EGFR, mutant K-Ras and mutant B-Raf, respectively. I also interact with Dana-Farber translational researchers to understand and develop predictors of sensitivity and resistance to targeted agents that can be incorporated into patient selection for trials.
Dana-Farber Cancer Institute450 Brookline AvenueBoston MA, 02215Get Directions